Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.
FDA's Patrizia Cavazzoni to retire as CDER chief in 2nd senior official's departure in span of weeks
The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...
These initiatives represent a way to accelerate access to treatments that have historically faced longer regulatory pathways.
With each new year comes a new set of accompanying challenges, from tackling the latest innovations to new incarnations of old issues. 2025 will be ...
The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...
FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.
The Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) issued a ...
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...
The FDA urges manufacturers to revise labeling of transmucosal buprenorphine products to ease access to higher doses because ...
Dr. Scott Manthei of the Nevada Ear and Sinus Institute has been advising patients against taking drugs like Sudafed for ...
The U.S. Food and Drug Administration has revoked authorization for Red No. 3 in food and ingested drugs in response to a ...
Trained on large databases of brain data among newborns, CergenX’s Wave device uses AI to help with earlier detection of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback